BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer by Goldie Y.L. Lui, Reid Shaw, Franz X. Schaub, Isabella N. Stork, Kay E. Gurley, Caroline Bridgwater, Robert L. Diaz, Rachele Rosati, Hallie A. Swan, Tan A. Ince, Thomas C. Harding, Vijayakrishna K. Gadi, Barbara A. Goff, Christopher J. Kemp, Elizabeth M. Swisher, Carla Grandori

Get full text

Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing by Heidi J. Gray, Payel Chatterjee, Rachele Rosati, Lauren R. Appleyard, Grace J. Durenberger, Robert L. Diaz, Hallie A. Swan, Danielle Peretti, Maddy Pollastro, Trevor Ainge, Katannya Kapeli, Shalini Pereira, Astrid L. Margossian, Kalyan Banda, Barbara A. Goff, Elizabeth M. Swisher, Brady Bernard, Christopher J. Kemp, Carla Grandori

Get full text